The estimated Net Worth of Michael Loughran is at least $45.4 Mille dollars as of 23 May 2006. Michael Loughran owns over 3,500 units of Hookipa Pharma Inc stock worth over $45,408 and over the last 19 years Michael sold HOOK stock worth over $0.
Michael has made over 3 trades of the Hookipa Pharma Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently Michael exercised 3,500 units of HOOK stock worth $35 on 23 May 2006.
The largest trade Michael's ever made was exercising 3,500 units of Hookipa Pharma Inc stock on 23 May 2006 worth over $35. On average, Michael trades about 1,283 units every 59 days since 2005. As of 23 May 2006 Michael still owns at least 8,600 units of Hookipa Pharma Inc stock.
You can see the complete history of Michael Loughran stock trades at the bottom of the page.
Michael's mailing address filed with the SEC is 14300 NE 145TH STREET, SUITE 210, , WOODINVILLE, WA, 98072.
Over the last 21 years, insiders at Hookipa Pharma Inc have traded over $12,222,300 worth of Hookipa Pharma Inc stock and bought 1,455,824 units worth $18,573,557 . The most active insiders traders include Group, Llc Green Jeremy Red..., Bros. Advisors Lp Baker Bro... e Deventer Sander Van. On average, Hookipa Pharma Inc executives and independent directors trade stock every 94 days with the average trade being worth of $180,581. The most recent stock trade was executed by Reinhard Kandera on 21 August 2023, trading 7,000 units of HOOK stock currently worth $5,110.
hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a
Hookipa Pharma Inc executives and other stock owners filed with the SEC include: